| abstract |
The present invention pertains to methods for determining gene expression signatures for diagnosing patients with prostate cancer, e.g., to establish a prognosis for such patients, for determining the predisposition of said patient to develop aggressive or indolent disease, for example after primary treatment, and/or for identification and stratification of patients for available therapies. The invention also relates to products used in such methods, e.g. kits, software, and the like. The present invention further relates to therapies for use in the treatment of patients that have been diagnosed, identified, or stratified in any of the methods disclosed herein. |